MARKET

NWBO

NWBO

Northwest Bio
OTCMQB
0.572
+0.028
+5.07%
Closed 15:52 03/01 EST
OPEN
0.548
PREV CLOSE
0.545
HIGH
0.590
LOW
0.548
VOLUME
622.87K
TURNOVER
355.06K
52 WEEK HIGH
2.150
52 WEEK LOW
0.386
MARKET CAP
660.23M
P/E (TTM)
-8.5022
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NWBO last week (0219-0223)?
Weekly Report · 6d ago
Weekly Report: what happened at NWBO last week (0212-0216)?
Weekly Report · 02/19 12:43
Weekly Report: what happened at NWBO last week (0205-0209)?
Weekly Report · 02/12 12:27
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
Northwest Biotherapeutics announces key development work for the flaskworks manufacturing system has been completed. The company is developing a system to manufacture DCVax® personalized immune therapies for solid tumor cancers. The patent coverage of the Flaskworks system has also been expanded. The Company believes the system will play a central role in enabling the efficient scale-up of manufacturing.
PR Newswire · 02/06 14:30
Weekly Report: what happened at NWBO last week (0129-0202)?
Weekly Report · 02/05 12:41
Weekly Report: what happened at NWBO last week (0122-0126)?
Weekly Report · 01/29 12:22
Weekly Report: what happened at NWBO last week (0115-0119)?
Weekly Report · 01/22 12:29
Weekly Report: what happened at NWBO last week (0108-0112)?
Weekly Report · 01/15 12:23
More
About NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.

Webull offers Northwest Biotherapeutics, Inc stock information, including OTCMQB: NWBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NWBO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NWBO stock methods without spending real money on the virtual paper trading platform.